+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Middle East & Africa Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel- Product Image
Middle East & Africa Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel- Product Image
Sale

Middle East & Africa Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel

  • PDF Icon

    Report

  • 134 Pages
  • February 2023
  • Region: Africa, Middle East
  • The Insight Partners
  • ID: 5743955
UP TO OFF until Jun 30th 2024
Description Jump to:
The Middle East & Africa pulmonary arterial hypertension market is expected to grow from US$ 410.88 million in 2022 to US$ 535.74 Million by 2028; it is estimated to grow at a CAGR of 4.5% from 2022 to 2028.

Growing Patent Expiration to Offer Lucrative Opportunities for Middle East & Africa Pulmonary Arterial Hypertension Market Growth During Forecast Period

Patent expiry permits generic drugs to enter the market and diversify product offerings. A few patented products are expected to become off-patent in the coming years, which is likely to provide an enormous opportunity for generic formulation companies. Many pharma companies such as finds Care Ratings are already working to develop the generic version of patented products. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to offer an opportunity for generic drug manufacturers to enter a new market. Hence, the growing patent expiration is expected to offer lucrative opportunities for the Middle East & Africa pulmonary arterial hypertension market growth in the coming years.

Middle East & Africa Pulmonary Arterial Hypertension Market Overview

The Middle East & Africa pulmonary arterial hypertension market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. Saudi Arabia is expected to account for the largest market share during the forecasted period i.e., from 2022 to 2028. Saudi Arabia is estimated to register considerable pulmonary arterial hypertension market growth. Saudi Arabia is the largest economy in the Middle East, excelling in the growth of various research and development programs across the nation. The country is becoming well-known in the field of pharmaceutical manufacturing. Furthermore, Saudi Arabia is expected to positively impact the Middle East & Africa pulmonary arterial hypertension market due to various regulations and the high demand for PAH drugs in the country. Additionally, several organizations are increasing awareness and knowledge about PAH among the population of Saudi Arabia. For instance, Saudi Association for Pulmonary Hypertension (SAPH) is working to increase awareness among people and knowledge of pulmonary vascular diseases among medical professionals in Saudi Arabia. Further, the government of Saudi Arabia launched the Saudi Vision 2030 program to reduce oil dependence and diversify other sectors, including healthcare, which is leading to significant development in healthcare services and a high adoption rate of advanced medical technologies. Under Vision 2030, the Saudi Arabian Government plans to invest over US$ 65 billion to develop the healthcare infrastructure in the country by prioritizing local production of pharmaceuticals and medical devices. Thus, the increasing awareness about PAH and the launch of Saudi Vision 2030 is expected to fuel the growth of the Middle East & Africa pulmonary arterial hypertension market in Saudi Arabia in the coming years.

Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

Middle East & Africa Pulmonary Arterial Hypertension Market Segmentation

The Middle East & Africa pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.
  • Based on drugs, the Middle East & Africa pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.
  • Based on type, the Middle East & Africa pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Middle East & Africa pulmonary arterial hypertension market.
  • Based on route of administration, the Middle East & Africa pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.
  • Based on distribution channel, the Middle East & Africa pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.
  • Based on country, the Middle East & Africa pulmonary arterial hypertension market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. In 2022, Saudi Arabia registered the largest share in the Middle East & Africa pulmonary arterial hypertension market.
Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Middle East & Africa pulmonary arterial hypertension market.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Pulmonary Arterial Hypertension Market - By Drugs
1.3.2 MEA Pulmonary Arterial Hypertension Market - By Type
1.3.3 MEA Pulmonary Arterial Hypertension Market - By Route of Administration
1.3.4 MEA Pulmonary Arterial Hypertension Market - By Distribution Channel
1.3.5 MEA Pulmonary Arterial Hypertension Market - By Country

2. MEA Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. MEA Pulmonary Arterial Hypertension Market - Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Experts Opinion

5. MEA Pulmonary Arterial Hypertension Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
5.2 Market Restraints
5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
5.3 Market Opportunities
5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
5.4 Future Trend
5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - MEA Analysis
6.1 MEA Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

7. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs
7.1 Overview
7.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
7.3 Endothelin Receptor Antagonists (ERAs)
7.3.1 Overview
7.3.2 Endothelin Receptor Antagonists (ERAs): MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Prostacyclin and Prostacyclin Analogs
7.4.1 Overview
7.4.2 Prostacyclin and Prostacyclin Analogs: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.5 SGC Stimulators
7.5.1 Overview
7.5.2 sGC Stimulators: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Pde-5 Dipsticks
7.6.1 Overview
7.6.2 Pde-5 Dipsticks: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. MEA Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type
8.1 Overview
8.2 MEA Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
8.3 Branded
8.3.1 Overview
8.3.2 Branded: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Generics
8.4.1 Overview
8.4.2 Generics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration
9.1 Overview
9.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
9.3 Oral
9.3.1 Overview
9.3.2 Oral: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Intravenous/ Subcutaneous
9.4.1 Overview
9.4.2 Intravenous/ Subcutaneous: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.5 Inhalational
9.5.1 Overview
9.5.2 Inhalational: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel
10.1 Overview
10.2 MEA Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
10.3 Hospital Pharmacies and Clinics
10.3.1 Overview
10.3.2 Hospital Pharmacies and Clinics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Online Pharmacies
10.4.1 Overview
10.4.2 Online Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.5 Retail Pharmacies
10.5.1 Overview
10.5.2 Retail Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Country Analysis
11.1 Overview
11.1.1 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.1.1.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.1.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.1.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.1.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.1.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.1.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.1.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.1.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.1.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.1.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.1.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.1.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.1.4 Rest of the MEA: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.1.1.4.1 Overview
11.1.1.4.2 Rest of the MEA: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.3 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.1.4.4 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.1.4.5 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.1.4.6 Rest of the MEA: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. MEA Pulmonary Arterial Hypertension Market - Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview

13. Company Profiles
13.1 Johnson & Johnson
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Gilead Sciences Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Novartis AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 GSK Plc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Lupin Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Pfizer Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

List of Tables
Table 1 MEA Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 2. UAE Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 3. UAE Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 4. UAE Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 5. UAE Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 6. Saudi Arabia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 7. Saudi Arabia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 8. Saudi Arabia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 9. Saudi Arabia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 10. South Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 11. South Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 12. South Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 13. South Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 14. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 15. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of the MEA Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of the MEA Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 18. Organic Developments in the MEA pulmonary arterial hypertension market
Table 19. Inorganic Developments in the MEA pulmonary arterial hypertension market
Table 20. Glossary of Terms

List of Figures
Figure 1. MEA Pulmonary Arterial Hypertension Market Segmentation
Figure 2. MEA Pulmonary Arterial Hypertension Market - By Country
Figure 3. MEA Pulmonary Arterial Hypertension Market Overview
Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of the MEA Pulmonary Arterial Hypertension Market
Figure 5. Saudi Arabia to Show Significant Growth During Forecast Period
Figure 6. MEA: PEST Analysis
Figure 7. Experts Opinion
Figure 8. MEA Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
Figure 9. MEA Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
Figure 10. MEA Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
Figure 11. Endothelin Receptor Antagonists (ERAs): MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 12. Prostacyclin and Prostacyclin Analogs: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 13. sGC Stimulators: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 14. Pde-5 Dipsticks: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 15. MEA Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
Figure 16. Branded: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 17. Generics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 18. MEA Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
Figure 19. Oral: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 20. Intravenous/ Subcutaneous: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Inhalational: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. MEA Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
Figure 23. Hospital Pharmacies and Clinics: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Online Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Retail Pharmacies: MEA Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 27. UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bayer AG
  • Gilead Sciences Inc
  • GSK Plc
  • Johnson & Johnson
  • Lupin Ltd
  • Novartis AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd

Table Information

Report AttributeDetails
No. of Pages134
PublishedFebruary 2023
Forecast Period2022 - 2028
Estimated Market Value ( USD ) in 2022 $ 410.88 Million
Forecasted Market Value ( USD ) by 2028 $ 535.74 Million
Compound Annual Growth Rate4.5%
Regions CoveredAfrica, Middle East

Related Topics

Related Reports

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028 - Product Image

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

  • Report
  • 190 Pages
  • Global
From
Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 250 Pages
  • Global
Global Pulmonary Arterial Hypertension Market by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5), Distribution (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Forecast 2024-2030 - Product Image

Global Pulmonary Arterial Hypertension Market by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5), Distribution (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Forecast 2024-2030

  • Report
  • 187 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 250 Pages
  • Global
From
Pulmonary Arterial Hypertension Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Pulmonary Arterial Hypertension Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 107 Pages
  • Global
From

About the Pulmonary Arterial Hypertension Drug Market

Pulmonary Arterial Hypertension (PAH) is a rare, progressive, and life-threatening form of high blood pressure that affects the arteries in the lungs and the right side of the heart. It is a type of cardiovascular disease, and is treated with a variety of drugs. These drugs are used to reduce symptoms, improve exercise capacity, and slow the progression of the disease. Commonly used drugs include prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. The PAH drug market is a rapidly growing segment of the cardiovascular drug market. It is driven by the increasing prevalence of PAH, the development of new drugs, and the increasing awareness of the disease. The market is expected to continue to grow in the coming years, as new drugs are developed and approved. Some of the major companies in the PAH drug market include Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.